Lattice Biologics Ltd. (LBLTF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lattice Biologics Ltd. (LBLTF) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. La acción obtiene una puntuación de 51/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 17 mar 2026Lattice Biologics Ltd. (LBLTF) Resumen de Asistencia Médica y Tuberías
Lattice Biologics Ltd. is a biotech company specializing in the development and marketing of biologic products for bone regeneration, including amniotic fluid-based products and allografts, primarily serving the dental, spine, and orthopedic markets globally, with a focus on enhancing surgical outcomes.
Tesis de Inversión
Lattice Biologics Ltd. presents a focused investment opportunity within the bone regeneration market. The company's amniotic fluid-based products, such as AmnioBoost and AmnioBlast, offer potential for growth in the regenerative medicine sector. With a gross margin of 41.4%, the company demonstrates an ability to generate revenue from its products. Key value drivers include the expansion of its product portfolio and penetration into new geographic markets. Upcoming catalysts include potential regulatory approvals for its amniotic fluid-based products and strategic partnerships to expand distribution channels. Potential risks include the company's negative profit margin of -60.2% and reliance on the OTC market for trading, which may impact liquidity and valuation.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Gross Margin of 41.4% indicates the company's ability to generate revenue from its products.
- Negative Profit Margin of -60.2% reflects ongoing challenges in achieving profitability.
- Beta of 1.21 suggests the stock is more volatile than the overall market.
- The company's focus on bone regeneration addresses a growing need in the dental, spine, and orthopedic markets.
- Lattice Biologics' amniotic fluid-based products offer potential for growth in the regenerative medicine sector.
Competidores y Pares
Fortalezas
- Proprietary amniotic fluid-based product technology.
- Focus on bone regeneration in specific surgical applications.
- Established relationships with surgeons and hospitals.
- Comprehensive portfolio of allograft options.
Debilidades
- Negative profit margin.
- Reliance on OTC market for trading.
- Limited market share compared to larger competitors.
- Dependence on regulatory approvals for new products.
Catalizadores
- Upcoming: Potential regulatory approvals for AmnioBoost and AmnioBlast products.
- Ongoing: Expansion of distribution channels through strategic partnerships.
- Ongoing: Clinical trials and research demonstrating product efficacy.
- Ongoing: Geographic expansion into new markets.
- Ongoing: Development of new products in related regenerative medicine areas.
Riesgos
- Ongoing: Negative profit margin and challenges in achieving profitability.
- Potential: Competition from established medical device companies.
- Potential: Regulatory hurdles and changes in healthcare policies.
- Ongoing: Reliance on OTC market for trading, impacting liquidity and valuation.
- Potential: Product liability claims.
Oportunidades de crecimiento
- Expansion of Amniotic Fluid-Based Products: Lattice Biologics can capitalize on the growing demand for regenerative medicine by expanding the applications and market reach of its AmnioBoost and AmnioBlast products. The amniotic fluid market is projected to grow significantly, driven by its regenerative properties and potential in various therapeutic areas. Successful clinical trials and regulatory approvals could drive adoption by surgeons and healthcare providers, leading to increased revenue and market share. Timeline: Ongoing.
- Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with established medical device companies or distributors can significantly expand Lattice Biologics' market access and sales reach. Leveraging existing distribution networks can accelerate product adoption and penetration into new geographic markets. These partnerships can also provide access to additional resources and expertise, enhancing the company's competitive position. Timeline: Ongoing.
- Geographic Expansion: Expanding into new geographic markets, particularly in Europe and Asia-Pacific, represents a significant growth opportunity for Lattice Biologics. These regions have a growing demand for advanced bone regeneration products. Adapting products to meet local regulatory requirements and establishing distribution channels in these markets can drive revenue growth and diversification. Timeline: 2-3 years.
- Product Portfolio Diversification: Diversifying the product portfolio beyond bone regeneration to include other regenerative medicine applications, such as wound healing and soft tissue repair, can expand Lattice Biologics' addressable market. Developing and launching new products in these areas can leverage the company's expertise in amniotic fluid-based technologies and address unmet clinical needs. Timeline: 3-5 years.
- Clinical Trials and Research: Investing in clinical trials and research to demonstrate the efficacy and safety of its products can enhance Lattice Biologics' credibility and market acceptance. Positive clinical data can support regulatory approvals and drive adoption by surgeons and healthcare providers. Collaborating with leading research institutions and publishing scientific studies can further strengthen the company's reputation and competitive advantage. Timeline: Ongoing.
Oportunidades
- Expansion of amniotic fluid-based product applications.
- Strategic partnerships and distribution agreements.
- Geographic expansion into new markets.
- Product portfolio diversification into related regenerative medicine areas.
Amenazas
- Competition from established medical device companies.
- Regulatory hurdles and changes in healthcare policies.
- Potential product liability claims.
- Economic downturns affecting healthcare spending.
Ventajas competitivas
- Proprietary amniotic fluid-based product technology.
- Established relationships with surgeons and hospitals.
- Focus on bone regeneration in specific surgical applications.
Acerca de LBLTF
Lattice Biologics Ltd., headquartered in Belgrade, Montana, is a biotech company focused on developing, manufacturing, and marketing biologic solutions for bone regeneration. The company's products are utilized in a variety of surgical applications across dental, spine, and general orthopedic fields. Lattice Biologics develops novel amniotic fluid-based products, including AmnioBoost and AmnioBlast, alongside a comprehensive portfolio of traditional allografts. These allografts encompass spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix options. The company's products are designed to enhance fusion in spine surgery, aid in breast reconstruction post-mastectomy, promote bone regeneration in foot and ankle procedures, and facilitate skull healing after neurosurgery. They also support wound repair in burn victims, hernia repair, and subchondral bone defect repair in knee and other joint surgeries, as well as address sports medicine indications, such as anterior and posterior cruciate ligament repair. Lattice Biologics aims to provide innovative and effective solutions for bone regeneration, addressing unmet needs in the surgical landscape.
Qué hacen
- Develops biologic products for bone regeneration.
- Manufactures allografts for dental, spine, and orthopedic applications.
- Markets products globally to healthcare providers and hospitals.
- Offers amniotic fluid-based products like AmnioBoost and AmnioBlast.
- Provides traditional allografts, including spinal, particulate, and soft tissue options.
- Addresses a range of surgical applications, including spine fusion and bone regeneration.
Modelo de Negocio
- Develops and manufactures biologic products for bone regeneration.
- Markets and sells these products to hospitals, surgeons, and other healthcare providers.
- Generates revenue through direct sales and distribution agreements.
Contexto de la Industria
Lattice Biologics operates within the medical devices industry, specifically focusing on bone regeneration. The industry is characterized by increasing demand for minimally invasive surgical techniques and regenerative medicine solutions. The competitive landscape includes companies offering allografts and synthetic bone substitutes. Lattice Biologics differentiates itself through its amniotic fluid-based products. The global bone graft and substitutes market is projected to reach billions of dollars by 2026, driven by an aging population and increasing incidence of orthopedic disorders.
Clientes Clave
- Hospitals and surgical centers
- Orthopedic surgeons
- Dental surgeons
- Spine surgeons
Finanzas
Gráfico e información
Precio de la acción de Lattice Biologics Ltd. (LBLTF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para LBLTF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para LBLTF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para LBLTF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de LBLTF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Donna Medina
CEO
Donna Medina serves as the CEO of Lattice Biologics Ltd. Her background includes extensive experience in the biotechnology and medical device industries. She has held leadership positions in various companies, focusing on strategic planning, product development, and commercialization. Her expertise spans across regenerative medicine, orthopedics, and surgical solutions. She has a proven track record of driving growth and innovation in the healthcare sector.
Historial: Under Donna Medina's leadership, Lattice Biologics has focused on expanding its product portfolio and market reach. Key milestones include the development and launch of novel amniotic fluid-based products and strategic partnerships to enhance distribution. She has also overseen efforts to strengthen the company's regulatory compliance and quality control processes. Her strategic decisions have aimed to position Lattice Biologics as a key player in the bone regeneration market.
Información del mercado OTC de LBLTF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Lattice Biologics may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier typically involves higher risks compared to exchanges like NYSE or NASDAQ due to less stringent listing standards and regulatory oversight.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Less stringent regulatory oversight compared to listed exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Analyze the company's capital structure and funding sources.
- Monitor news and press releases for any red flags.
- Consult with a qualified financial advisor.
- The company develops and markets biologic products for bone regeneration.
- The company has a CEO and management team in place.
- The company has a portfolio of products, including amniotic fluid-based products and allografts.
- The company's products are used in a range of surgical applications.
- The company is headquartered in Belgrade, Montana.
Preguntas Comunes Sobre LBLTF
¿Cuáles son los factores clave para evaluar LBLTF?
Lattice Biologics Ltd. (LBLTF) actualmente tiene una puntuación IA de 51/100, indicando puntuación moderada. Fortaleza clave: Proprietary amniotic fluid-based product technology.. Riesgo principal a monitorear: Ongoing: Negative profit margin and challenges in achieving profitability.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de LBLTF?
LBLTF actualmente puntúa 51/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de LBLTF?
Los precios de LBLTF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre LBLTF?
La cobertura de analistas para LBLTF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en LBLTF?
Las categorías de riesgo para LBLTF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Negative profit margin and challenges in achieving profitability.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de LBLTF?
La relación P/E para LBLTF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está LBLTF sobrevalorada o infravalorada?
Determinar si Lattice Biologics Ltd. (LBLTF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de LBLTF?
Lattice Biologics Ltd. (LBLTF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.